000 03592nam a2200433 c 4500
710 2 _aSpringerLink (Online service)
_9106996
999 _c117893
_d117893
_x1
001 117893
003 ES-MaUEC
005 20230102113832.0
006 a||||fo|||| 00| 0
007 cr nn nnnaamaa
008 191106s2019 si a o |||| 0|eng d
020 _a9789811394355
024 7 _a10.1007/978-981-13-9435-5
_2doi
040 _aES-MaUEC
_bspa
_cES-MaUEC
_dES-MaUEC
050 4 _aQK603
_b2019 EB
245 0 0 _aRecent Trends in Human and Animal Mycology
_cedited by Karuna Singh, Neelabh Srivastava.
250 _aFirst edition
264 1 _aSingapore
_bSpringer International Publishing
_c2019
300 _a1 recurso en línea (XVII, 280 páginas)
_b81 ilustraciones, 51 ilustraciones a color
336 _2rdacontent
_aTexto
_btxt
337 _2rdamedia
_aelectrónico
_bc
338 _2rdacarrier
_arecurso electrónico
_bcr
347 _atext file
_bPDF
490 0 _aBiomedical and Life Sciences (Springer-11642)
505 0 _aPart I Human and Animal Mycoses -- Pythiosis -- Superficial Mycoses in Dogs and Cats -- Pathogenic Chrysosporium-related Fungi in Reptiles and Other Animals -- Aspergillosis in Humans and Animals -- Some Clinically Significant Genera of Dematiaceous Hyphomycetes: An Update -- Endemic Mycoses in Americas -- Part II Mycotoxins in Relation to Human and Animal Health -- Mycotoxins and Their Inhalatory Intake Risk -- Tenuazonic acid:A Potent Mycotoxin -- Part III Antifungal Therapeutic Candidates -- Phytochemicals: New Avenues in Anti-Candidal Activity -- Recent Advances in Coumarins as Antifungal Agents.
520 3 _aFungal pathogens pose an on-going and serious threat for poikilotherms and homeotherms, and can cause a broad spectrum of diseases ranging from innocuous to life-threatening. In addition, long-term exposure to some mycotoxigenic moulds can lead to mycotoxicoses in human and animals. Given the expanding population of immune compromised hosts, the list of fungal opportunists grows longer every year. Moreover, antifungal resistance, drug-related toxicity and our limited arsenal of antifungals have exacerbated the situation. To address these problems, strategies such as the identification of novel targets, use of the structure-activity relationship in rational drug design, development of new formulations, modification of existing antifungals to combat resistance, and bioavailability enhancement are called for. For the reader's convenience, this book has been divided into three sections. The first six chapters of Section I provide a timely review of mycoses, from endemic to cosmopolitan and from generalized to specific, while both chapters of Section II focus on risks associated with mycotoxins. In closing, the two chapters of Section III describe potential antifungal leads and drug candidates based on phytochemicals and coumarin scaffold.
988 _aPrimersemestre_2020_BiomedLife
650 7 _2embne
_9138682
_aMicología
700 1 _aSingh, Karuna
_eeditor literario
_4edt
_4http://id.loc.gov/vocabulary/relators/edt
700 1 _aSrivastava, Neelabh
_eeditor literario
_4edt
_4http://id.loc.gov/vocabulary/relators/edt
773 0 _tSpringer eBooks
776 0 8 _iPrinted edition:
_z9789811394348
776 0 8 _iPrinted edition:
_z9789811394362
776 0 8 _iPrinted edition:
_z9789811394379
856 4 0 _uhttps://go.openathens.net/redirector/universidadeuropea.es?url=https://doi.org/10.1007/978-981-13-9435-5
_zAcceso a este recurso digital (usuarios Universidad Europea de Madrid)
942 _2lcc
_cLE
_n0
998 _b03/2020
_dz
_ek
_zSI